$GTHX Roth Capital Maintains Buy on G1 Therapeutics, Lowers Price Target to $56 Roth Capital analyst Tony Butler maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $57 to $56. Benzinga · 09/01/2021 08:30 Roth Capital analyst Tony Butler maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $57 to $56.